Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer

Ramez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patien...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eskander RN, Tewari KS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/45c2c02ff8e54951b639934194324e47
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45c2c02ff8e54951b639934194324e47
record_format	dspace
spelling	oai:doaj.org-article:45c2c02ff8e54951b639934194324e472021-12-02T02:00:22ZEpithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer1179-1438https://doaj.org/article/45c2c02ff8e54951b639934194324e472013-10-01T00:00:00Zhttp://www.dovepress.com/epithelial-cell-adhesion-molecule-directed-trifunctional-antibody-immu-a14572https://doaj.org/toc/1179-1438Ramez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced-stage ovarian cancer. Recently, immune modulation has gained attention as a novel approach to anti-cancer therapy. This review explores the role of epithelial cell-adhesion molecule (EpCAM)-directed immunotherapy, with a specific focus on the mechanism of action of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. Keywords: ovarian cancer, immunotherapy, catumaxomab, CD3, EpCAMEskander RNTewari KSDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2013, Iss Supplement 1, Pp 55-61 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Eskander RN Tewari KS Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
description	Ramez N Eskander, Krishnansu S Tewari Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced-stage ovarian cancer. Recently, immune modulation has gained attention as a novel approach to anti-cancer therapy. This review explores the role of epithelial cell-adhesion molecule (EpCAM)-directed immunotherapy, with a specific focus on the mechanism of action of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed. Keywords: ovarian cancer, immunotherapy, catumaxomab, CD3, EpCAM
format	article
author	Eskander RN Tewari KS
author_facet	Eskander RN Tewari KS
author_sort	Eskander RN
title	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
title_short	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
title_full	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
title_fullStr	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
title_full_unstemmed	Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
title_sort	epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/45c2c02ff8e54951b639934194324e47
work_keys_str_mv	AT eskanderrn epithelialcelladhesionmoleculedirectedtrifunctionalantibodyimmunotherapyforsymptommanagementofadvancedovariancancer AT tewariks epithelialcelladhesionmoleculedirectedtrifunctionalantibodyimmunotherapyforsymptommanagementofadvancedovariancancer
_version_	1718402771795836928

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer

Ejemplares similares